Earnings ·
Eikon Therapeutics reported second quarter 2026 financial results and clinical updates
EIKNEikon Therapeutics, Inc.
Eikon Therapeutics reported second quarter 2026 financial results and clinical updates. The company ended the quarter with $531.2 million in cash, cash equivalents, and marketable securities. Research and development expenses were $75.5 million, while general and administrative expenses decreased to $17.9 million due to prior-year impairment charges. Net loss attributable to common stockholders was $88.4 million. Clinically, EIK1001 advanced through a first interim analysis in the TeLuRide-006 registrational trial for melanoma, and seven abstracts were accepted for presentation at the ESMO Congress 2026. The company also appointed Ma. Fatima Francisco to its Board of Directors. Eikon Therapeutics is a late-stage clinical biopharmaceutical company developing innovative oncology medicines.